AGA临床实践更新:非酒精性脂肪性肝病患者肝细胞癌筛查与监测专家综述
非酒精性脂肪性肝病(NAFLD)影响全球超过25%人口,其中高达四分之一可能为非酒精性脂肪性肝炎(NASH),与肝硬化、肝衰竭和肝细胞癌(HCC)等并发症相关。HCC是全球第五常见癌症及第二癌症死亡原因,NAFLD已成为其快速新兴风险因素。NAFLD相关肝癌可能在无肝硬化背景下发生,常晚期诊断且接受根治治疗机会低、生存差,但现有指南对非肝硬化NAFLD患者的HCC监测推荐有限。本文基于证据综述NAFLD患者HCC风险并提供最佳实践建议。
要点
- NAFLD影响全球超过25%人口,高达1/4患者可能有NASH。
- NAFLD相关HCC可在无肝硬化时发生,常晚期诊断且预后较差。
- 现有指南对非肝硬化NAFLD患者的HCC监测推荐有限,需个体化评估。
核心结论
- NAFLD是HCC快速新兴风险因素,HCC可在无肝硬化背景下发生,常晚期诊断且根治机会低、生存差。
- 现有学会指南对非肝硬化NAFLD患者的HCC监测推荐有限,本文提供最佳实践建议以指导临床管理。
研究设计与样本
- 专家综述:基于证据的综述,针对NAFLD患者HCC风险提供最佳实践建议。
- 原文未报告系统检索范围、样本量或研究类型。
主要发现
- NAFLD影响美国及全球超过25%人口,高达1/4的NAFLD患者可能有NASH。
- NASH与肝硬化并发症、肝功能失代偿和HCC导致的显著发病率和死亡率相关。
- HCC是全球第五常见癌症及第二癌症死亡原因,NAFLD已被确定为该恶性肿瘤的快速新兴风险因素。
- NAFLD相关肝脏并发症预计在未来十年成为肝移植的主要指征。
- NAFLD相关HCC可能在无肝硬化时发生,常晚期诊断,接受根治治疗机会低且生存较差。
关键数值与推荐
- 原文未报告具体的监测阈值、筛查工具频率或风险分层标准。
临床怎么用
- 临床医生应认识到NAFLD患者(包括无肝硬化者)存在HCC风险,需评估个体风险。
- 对NAFLD相关HCC监测应参考本文最佳实践建议,综合考虑宿主和疾病相关风险因素。
- 原文未提供具体监测工具、频率或谁应监测的明确推荐。
局限性
- 目前指导NAFLD患者HCC监测的数据有限,包括哪些患者应监测、最佳筛查工具、监测频率及共存风险因素的影响。
- 现有学会指南对非肝硬化NAFLD患者的HCC监测推荐有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nonalcoholic fatty liver disease (NAFLD) is a leading etiology for chronic liver disease with an immense public health impact and affects >25% of the US and global population. Up to 1 in 4 NAFLD patients may have nonalcoholic steatohepatitis (NASH). NASH is associated with significant morbidity and mortality due to complications of liver cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC). Recent data confirm that HCC represents the fifth most common cancer and is the second leading cause of cancer-related death worldwide, and NAFLD has been identified as a rapidly emerging risk factor for this malignancy. NAFLD-associated liver complications are projected to become the leading indication for liver transplantation in the next decade. Despite evidence that NAFLD-associated HCC may arise in the absence of cirrhosis, is often diagnosed at advanced stages, and is associated with lower receipt of curative therapy and with poorer survival, current society guidelines provide limited guidance/recommendations addressing HCC surveillance in patients with NAFLD outside the context of established cirrhosis. Limited data are presently available to guide clinicians with respect to which patients with NAFLD should undergo HCC surveillance, optimal screening tools, frequency of monitoring, and the influence of coexisting host- and disease-related risk factors. Herein we present an evidence-based review addressing HCC risk in patients with NAFLD and provide Best Practice Advice statements to address key issues in clinical management.
引用
- Loomba R, Lim JK, Patton H, et al. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology. 2020. PMID: 32006545. doi:10.1053/j.gastro.2019.12.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。